Alvogen’s sister company, Alvotech, is a uniquely positioned biopharmaceutical business that focuses purely on the biosimilar market with complete vertical integration from early R&D to commercial manufacturing. Current biosimilar assets include follow-on versions of seven leading monoclonal antibodies molecules, which will be brought to market after patent expiries.
Alvotech is uniquely positioned with a fully integrated R&D and manufacturing engine, driven by best-in-class in-house research and development. Its state-of-the-art manufacturing facility fill finish capacity, situated in a patent-friendly location in Reykjavik, Iceland. Rasmus Rojkjaer leads the Alvotech team with over 200 colleagues who are passionate about transforming patients’ lives and bringing high-quality biopharmaceuticals to market.